Phage therapy targetingEscherichia coli—a story with no end?
Authors:
Open Access
- 9 November 2016
- journal article
- review article
- Published by Oxford University Press (OUP) in FEMS Microbiology Letters
- Vol. 363 (22)
Abstract
Bacteriophages (phages) or bacterial viruses have long been proposed as an alternative therapy against antibiotic-resistant bacteria such as Escherichia coli. Even though poorly documented in the scientific literature, a long clinical history of phage therapy in countries such as Russia and Georgia suggests potential value in the use of phages as antibacterial agents. Escherichia coli is responsible for a wide range of diseases, intestinal (diarrhoea) and extraintestinal (UTI, septicaemia, pneumoniae, meningitis), making it an ideal target for phage therapy. This review discusses the latest research focusing on the potential of phage therapy to tackle E. coli-related illnesses. No intact phages are approved in EU or USA for human therapeutic use, but many successful in vitro and in vivo studies have been reported. However, additional research focused on in vivo multispecies models and human trials are required if phage therapy targeting E. coli pathotypes can be a story with happy end.Keywords
This publication has 45 references indexed in Scilit:
- In vivo efficacy of single phage versus phage cocktail in resolving burn wound infection in BALB/c miceMicrobial Pathogenesis, 2016
- Modelling the interaction between bacteriophages and their bacterial hostsMathematical Biosciences, 2016
- Prevalence of Escherichia coli Virulence Genes in Patients with Diarrhea and a Subpopulation of Healthy Volunteers in Madrid, SpainFrontiers in Microbiology, 2016
- Evaluation of the Efficacy of a Bacteriophage in the Treatment of Pneumonia Induced by Multidrug ResistanceKlebsiella pneumoniaein MiceBioMed Research International, 2015
- Understanding Host-Adherent-InvasiveEscherichia coliInteraction in Crohn’s Disease: Opening Up New Therapeutic StrategiesBioMed Research International, 2014
- Adherent-invasive Escherichia coli (AIEC) in pediatric Crohn’s disease patients: phenotypic and genetic pathogenic featuresBMC Research Notes, 2014
- Bacteriophages with the Ability to Degrade Uropathogenic Escherichia Coli BiofilmsViruses, 2012
- Infection strategies of enteric pathogenic Escherichia coliGut Microbes, 2012
- Bacteriophages2009
- Phage therapy: the Escherichia coli experienceMicrobiology, 2005